Annexon Inc
ANNX5.180USD
+0.070+1.37%
Close 12/24, 13:00（ET）Quotes delayed by 15 min
596.33MMarket Cap
LossP/E TTM
More Details of Annexon Inc Company
Annexon, Inc. is a clinical-stage biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical complement-mediated neuroinflammatory diseases of the body, brain, and eye. It identifies and characterizes the role of the classical complement pathway in three therapeutic areas: autoimmune, neurodegeneration and ophthalmology, using its proprietary platform. Its lead candidate, ANX005, an investigational, full-length monoclonal antibody (mAb), is formulated for intravenous administration as the potential first targeted treatment for patients with Guillain-Barre Syndrome (GBS). It is advancing ANX1502, a novel small-molecule inhibitor of classical complement designed for oral administration in a range of chronic autoimmune diseases. It is also advancing ANX007, designed to block C1q locally in the eye, to provide complete protection against excess classical complement activity and the loss of photoreceptor neurons.
Annexon Inc Info
Ticker SymbolANNX
Company nameAnnexon Inc
IPO dateJul 24, 2020
CEOLove (Douglas E)
Number of employees100
Security typeOrdinary Share
Fiscal year-endJul 24
Address1400 Sierra Point Parkway
CityBRISBANE
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code94005
Phone16508225500
Websitehttps://annexonbio.com/
Ticker SymbolANNX
IPO dateJul 24, 2020
CEOLove (Douglas E)
Company Executives of Annexon Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Michael Overdorf
Mr. Michael Overdorf
Executive Vice President, Chief Business Officer
Executive Vice President, Chief Business Officer
81.75K
-1.03%
Ms. Jennifer Lew
Ms. Jennifer Lew
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
81.33K
-1.35%
Dr. Ted Yednock, Ph.D.
Dr. Ted Yednock, Ph.D.
Executive Vice President, Chief Innovation Officer
Executive Vice President, Chief Innovation Officer
24.66K
-4.33%
Dr. Jamie Dananberg, M.D.
Dr. Jamie Dananberg, M.D.
Executive Vice President, Chief Medical Officer
Executive Vice President, Chief Medical Officer
7.48K
-90.47%
Dr. Dean Rick Artis, Ph.D.
Dr. Dean Rick Artis, Ph.D.
Executive Vice President, Chief Scientific Officer
Executive Vice President, Chief Scientific Officer
--
--
Mr. William D. Waddill
Mr. William D. Waddill
Independent Director
Independent Director
--
--
Ms. Jung E. Choi
Ms. Jung E. Choi
Independent Director
Independent Director
--
--
Dr. William H. Carson, M.D.
Dr. William H. Carson, M.D.
Independent Director
Independent Director
--
--
Mr. Muneer A. Satter, J.D.
Mr. Muneer A. Satter, J.D.
Independent Director
Independent Director
--
--
Mr. William (Bj) Jones, Jr.
Mr. William (Bj) Jones, Jr.
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Michael Overdorf
Mr. Michael Overdorf
Executive Vice President, Chief Business Officer
Executive Vice President, Chief Business Officer
81.75K
-1.03%
Ms. Jennifer Lew
Ms. Jennifer Lew
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
81.33K
-1.35%
Dr. Ted Yednock, Ph.D.
Dr. Ted Yednock, Ph.D.
Executive Vice President, Chief Innovation Officer
Executive Vice President, Chief Innovation Officer
24.66K
-4.33%
Dr. Jamie Dananberg, M.D.
Dr. Jamie Dananberg, M.D.
Executive Vice President, Chief Medical Officer
Executive Vice President, Chief Medical Officer
7.48K
-90.47%
Dr. Dean Rick Artis, Ph.D.
Dr. Dean Rick Artis, Ph.D.
Executive Vice President, Chief Scientific Officer
Executive Vice President, Chief Scientific Officer
--
--
Mr. William D. Waddill
Mr. William D. Waddill
Independent Director
Independent Director
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Mon, Nov 17
Updated: Mon, Nov 17
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Alerce Investment Management, L.P.
6.73%
BlackRock Institutional Trust Company, N.A.
4.91%
BVF Partners L.P.
4.84%
Redmile Group, LLC
4.36%
Fidelity Institutional Asset Management
4.14%
Other
75.02%
Shareholders
Shareholders
Proportion
Alerce Investment Management, L.P.
6.73%
BlackRock Institutional Trust Company, N.A.
4.91%
BVF Partners L.P.
4.84%
Redmile Group, LLC
4.36%
Fidelity Institutional Asset Management
4.14%
Other
75.02%
Shareholder Types
Shareholders
Proportion
Investment Advisor
34.52%
Hedge Fund
17.68%
Investment Advisor/Hedge Fund
15.37%
Private Equity
6.73%
Research Firm
4.12%
Individual Investor
0.44%
Endowment Fund
0.33%
Bank and Trust
0.26%
Family Office
0.10%
Other
20.43%
Institutional Shareholding
Updated: Mon, Dec 8
Updated: Mon, Dec 8
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
326
114.34M
87.99%
+2.37M
2025Q3
332
111.98M
117.07%
+1.75M
2025Q2
327
110.87M
120.59%
-2.74M
2025Q1
331
111.53M
128.12%
-29.03M
2024Q4
321
116.52M
125.08%
+3.18M
2024Q3
294
113.52M
124.58%
+3.02M
2024Q2
280
110.20M
112.90%
+10.89M
2024Q1
276
95.92M
114.20%
-7.41M
2023Q4
266
81.20M
93.20%
+27.04M
2023Q3
268
54.17M
144.34%
-427.51K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Alerce Investment Management, L.P.
7.41M
6.74%
--
--
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
7.16M
6.52%
-458.35K
-6.02%
Jun 30, 2025
BVF Partners L.P.
7.00M
6.37%
--
--
Jun 30, 2025
Redmile Group, LLC
6.30M
5.73%
--
--
Jun 30, 2025
Fidelity Institutional Asset Management
5.08M
4.62%
+5.08M
--
Jun 30, 2025
The Vanguard Group, Inc.
5.37M
4.88%
+3.25K
+0.06%
Jun 30, 2025
Bain Capital Life Sciences Investors, LLC
5.25M
4.78%
--
--
Jun 30, 2025
Bellevue Asset Management AG
5.16M
4.69%
--
--
Jun 30, 2025
Fidelity Management & Research Company LLC
10.62M
9.66%
-2.64M
-19.93%
Jun 30, 2025
Millennium Management LLC
2.51M
2.29%
+2.34M
+1334.16%
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
Virtus LifeSci Biotech Clinical Trials ETF
0.79%
iShares Neuroscience and Healthcare ETF
0.72%
ALPS Medical Breakthroughs ETF
0.13%
ProShares Ultra Nasdaq Biotechnology
0.06%
iShares Micro-Cap ETF
0.06%
Avantis US Small Cap Equity ETF
0.04%
Invesco Nasdaq Biotechnology ETF
0.03%
iShares Russell 2000 Value ETF
0.03%
iShares Biotechnology ETF
0.03%
Invesco RAFI US 1500 Small-Mid ETF
0.03%
View more
Virtus LifeSci Biotech Clinical Trials ETF
Proportion0.79%
iShares Neuroscience and Healthcare ETF
Proportion0.72%
ALPS Medical Breakthroughs ETF
Proportion0.13%
ProShares Ultra Nasdaq Biotechnology
Proportion0.06%
iShares Micro-Cap ETF
Proportion0.06%
Avantis US Small Cap Equity ETF
Proportion0.04%
Invesco Nasdaq Biotechnology ETF
Proportion0.03%
iShares Russell 2000 Value ETF
Proportion0.03%
iShares Biotechnology ETF
Proportion0.03%
Invesco RAFI US 1500 Small-Mid ETF
Proportion0.03%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Annexon Inc?
The top five shareholders of Annexon Inc are:
Alerce Investment Management, L.P. holds 7.41M shares, accounting for 6.74% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 7.16M shares, accounting for 6.52% of the total shares.
BVF Partners L.P. holds 7.00M shares, accounting for 6.37% of the total shares.
Redmile Group, LLC holds 6.30M shares, accounting for 5.73% of the total shares.
Fidelity Institutional Asset Management holds 5.08M shares, accounting for 4.62% of the total shares.
Alerce Investment Management, L.P. holds 7.41M shares, accounting for 6.74% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 7.16M shares, accounting for 6.52% of the total shares.
BVF Partners L.P. holds 7.00M shares, accounting for 6.37% of the total shares.
Redmile Group, LLC holds 6.30M shares, accounting for 5.73% of the total shares.
Fidelity Institutional Asset Management holds 5.08M shares, accounting for 4.62% of the total shares.
What are the top three shareholder types of Annexon Inc?
The top three shareholder types of Annexon Inc are:
Alerce Investment Management, L.P.
BlackRock Institutional Trust Company, N.A.
BVF Partners L.P.
Alerce Investment Management, L.P.
BlackRock Institutional Trust Company, N.A.
BVF Partners L.P.
How many institutions hold shares of Annexon Inc (ANNX)?
As of 2025Q4, 326 institutions hold shares of Annexon Inc, with a combined market value of approximately 114.34M, accounting for 87.99% of the total shares. Compared to 2025Q3, institutional shareholding has increased by -29.08%.
What is the biggest source of revenue for Annexon Inc?
In --, the -- business generated the highest revenue for Annexon Inc, amounting to -- and accounting for --% of total revenue.
